The Bcl-2 gene has been demonstrated to be highly expressed in blood cancers, and the level of Bcl-2 expression has been found to be elevated in the accelerated/blastic phase of CML cells compared to the chronic stage which might drive the progression to the advanced stages [10]. This evidence concerns the gene BCL2 and hematopoietic and lymphoid system neoplasm.